Dengue Type 4 Live-Attenuated Vaccine Viruses Passaged in Vero Cells Affect Genetic Stability and Dengue-Induced Hemorrhaging in Mice

Most live-attenuated tetravalent dengue virus vaccines in current clinical trials are produced from Vero cells. In a previous study we demonstrated that an infectious cDNA clone-derived dengue type 4 (DEN-4) virus retains higher genetic stability in MRC-5 cells than in Vero cells. For this study we investigated two DEN-4 viruses: the infectious cDNA clone-derived DEN-4 2A and its derived 3′ NCR 30-nucleotide deletion mutant DEN-4 2AΔ30, a vaccine candidate. Mutations in the C-prM-E, NS2B-NS3, and NS4B-NS5 regions of the DEN genome were sequenced and compared following cell passages in Vero and MRC-5 cells. Our results indicate stronger genetic stability in both viruses following MRC-5 cell passages, leading to significantly lower RNA polymerase error rates when the DEN-4 virus is used for genome replication. Although no significant increases in virus titers were observed following cell passages, DEN-4 2A and DEN-4 2AΔ30 virus titers following Vero cell passages were 17-fold to 25-fold higher than titers following MRC-5 cell passages. Neurovirulence for DEN-4 2A and DEN-4 2AΔ30 viruses increased significantly following passages in Vero cells compared to passages in MRC-5 cells. In addition, more severe DEN-induced hemorrhaging in mice was noted following DEN-4 2A and DEN-4 2AΔ30 passages in Vero cells compared to passages in MRC-5 cells. Target mutagenesis performed on the DEN-4 2A infectious clone indicated that single point mutation of E-Q438H, E-V463L, NS2B-Q78H, and NS2B-A113T imperatively increased mouse hemorrhaging severity. The relationship between amino acid mutations acquired during Vero cell passage and enhanced DEN-induced hemorrhages in mice may be important for understanding DHF pathogenesis, as well as for the development of live-attenuated dengue vaccines. Taken together, the genetic stability, virus yield, and DEN-induced hemorrhaging all require further investigation in the context of live-attenuated DEN vaccine development.

[1]  B. Wu-Hsieh,et al.  Dengue Hemorrhage in a Mouse Model , 2009, Annals of the New York Academy of Sciences.

[2]  F. Guirakhoo,et al.  High Fidelity of Yellow Fever Virus RNA Polymerase , 2004, Journal of Virology.

[3]  D. Fairlie,et al.  Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor. , 1999, The Journal of general virology.

[4]  J. Joseph,et al.  Serotype-Specific Structural Differences in the Protease-Cofactor Complexes of the Dengue Virus Family , 2009, Journal of Virology.

[5]  J. Hombach,et al.  WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009. , 2010, Vaccine.

[6]  S. Halstead,et al.  Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. , 2005, Vaccine.

[7]  F. Guirakhoo,et al.  Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE) , 2001, Journal of Virology.

[8]  C. Rice,et al.  Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites , 1991, Journal of virology.

[9]  R. Edelman,et al.  Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. , 2003, The American journal of tropical medicine and hygiene.

[10]  D. Vaughn,et al.  Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. , 2003, The American journal of tropical medicine and hygiene.

[11]  F. Guirakhoo,et al.  Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates , 2004, Journal of Virology.

[12]  F. Guirakhoo,et al.  Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates , 2000, Journal of Virology.

[13]  T. Chambers,et al.  Yellow fever virus NS2B-NS3 protease: charged-to-alanine mutagenesis and deletion analysis define regions important for protease complex formation and function. , 2000, Virology.

[14]  B. Murphy,et al.  Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. , 2003, Vaccine.

[15]  Duane J. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[16]  D. Gubler.  The global emergence/resurgence of arboviral diseases as public health problems. , 2002, Archives of medical research.

[17]  C. Lai,et al.  Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins , 1991, Journal of virology.

[18]  T. Scott,et al.  Consequences of the Expanding Global Distribution of Aedes albopictus for Dengue Virus Transmission , 2010, PLoS neglected tropical diseases.

[19]  Suh-Chin Wu,et al.  High Genetic Stability of Dengue Virus Propagated in MRC-5 Cells as Compared to the Virus Propagated in Vero Cells , 2008, PloS one.

[20]  D. Gubler.  Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. , 2002, Trends in microbiology.

[21]  S. Halstead,et al.  Dengue virus-mosquito interactions. , 2008, Annual review of entomology.

[22]  F. Guirakhoo,et al.  Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.

[23]  R. Karron,et al.  rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. , 2005, The Journal of infectious diseases.

[24]  D. Vaughn,et al.  Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. , 2003, The American journal of tropical medicine and hygiene.

[25]  R. Karron,et al.  rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers , 2005 .

[26]  K. Murthy,et al.  Yellow fever virus NS2B-NS3 protease: characterization of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage activities. , 2005, The Journal of general virology.

[27]  F. Hofman,et al.  Both Virus and Tumor Necrosis Factor Alpha Are Critical for Endothelium Damage in a Mouse Model of Dengue Virus-Induced Hemorrhage , 2007, Journal of Virology.

[28]  J. Roehrig,et al.  Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. , 1997, Virology.

[29]  D. Vaughn,et al.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.

[30]  D. Webster,et al.  Progress towards a dengue vaccine. , 2009, The Lancet. Infectious diseases.

[31]  F. Guirakhoo,et al.  Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. , 2002, Virology.

[32]  C. Rice,et al.  Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties , 1999, Journal of Virology.

[33]  R. Yusof,et al.  Purified NS2B/NS3 Serine Protease of Dengue Virus Type 2 Exhibits Cofactor NS2B Dependence for Cleavage of Substrates with Dibasic Amino Acids in Vitro* , 2000, The Journal of Biological Chemistry.

[34]  B. Murphy,et al.  Prospects for a dengue virus vaccine , 2007, Nature Reviews Microbiology.

[35]  J. Lang,et al.  Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children , 2004, The Pediatric infectious disease journal.

[36]  B. Murphy,et al.  Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. , 2002, Virology.

[37]  E. Harris,et al.  Control of dengue virus translation and replication. , 2010, Current topics in microbiology and immunology.

[38]  A. Durbin,et al.  Dengue vaccine candidates in development. , 2010, Current topics in microbiology and immunology.

[39]  D. Vaughn,et al.  Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults , 2009, Human vaccines.

[40]  J. Lang,et al.  Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. , 2002, The American journal of tropical medicine and hygiene.

[41]  R. Chanock,et al.  Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys , 1996, Journal of virology.

[42]  Zheng Yin,et al.  Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus , 2006, Nature Structural &Molecular Biology.

[43]  M. Bray,et al.  Evaluation of molecular strategies to develop a live dengue vaccine. , 1998, Clinical and diagnostic virology.

[44]  N. Bhamarapravati,et al.  Live attenuated tetravalent dengue vaccine. , 2000, Vaccine.

[45]  C. Huang,et al.  Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development , 2003, Journal of Virology.

[46]  C. Huang,et al.  Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine , 2000, Journal of Virology.

[47]  M. Bray,et al.  Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Viral Vaccine Production in Cell Culture , 2010 .

[49]  S. Halstead,et al.  Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.